RSI Oversold Stocks
BCAB is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
BIOATLA INC (BCAB) Stock Price & Overview
NASDAQ:BCAB • US09077B1044
Current stock price
4.3 USD
+0.03 (+0.7%)
Last:
The current stock price of BCAB is 4.3 USD. Today BCAB is up by 0.7%. In the past month the price decreased by -53.15%. In the past year, price decreased by -73.63%.
BCAB Key Statistics
52-Week Range3.92 - 71.5
Current BCAB stock price positioned within its 52-week range.
1-Month Range3.92 - 10.25
Current BCAB stock price positioned within its 1-month range.
- Market Cap
- 356.255M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -50.50
- Dividend Yield
- N/A
BCAB Stock Performance
Today
+0.7%
1 Week
-8.37%
1 Month
-53.15%
3 Months
-73.49%
Longer-term
6 Months -89.71%
1 Year -73.63%
2 Years -96.21%
3 Years -97.47%
5 Years -99.83%
10 Years N/A
BCAB Stock Chart
BCAB Stock Screens
BCAB currently appears in the following ChartMill screener lists.
BCAB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BCAB. When comparing the yearly performance of all stocks, BCAB is a bad performer in the overall market: 98.48% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
BCAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BCAB. BCAB has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BCAB Earnings
On March 31, 2026 BCAB reported an EPS of -8 and a revenue of 2.00M. The company beat EPS expectations (34.64% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$8.00
Revenue Reported2M
EPS Surprise 34.64%
Revenue Surprise %
BCAB Forecast & Estimates
Analysts
Analysts85.71
Price TargetN/A
EPS Next Y7.09%
Revenue Next YearN/A
BCAB Groups
Sector & Classification
BCAB Financial Highlights
Over the last trailing twelve months BCAB reported a non-GAAP Earnings per Share(EPS) of -50.5. The EPS increased by 29.86% compared to the year before.
Income Statements
Revenue(TTM)2.00M
Net Income(TTM)-59.61M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -431.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%46.67%
Sales Q2Q%N/A
EPS 1Y (TTM)29.86%
Revenue 1Y (TTM)-81.82%
BCAB Ownership
Ownership
Inst Owners20.44%
Shares82.85M
Float77.67M
Ins Owners4.59%
Short Float %N/A
Short Ratio1.23
BCAB Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 371.899B | ||
| AMGN | AMGEN INC | 15.21 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.7 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.57 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.16 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.12 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.89 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.76 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCAB
Company Profile
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Company Info
IPO: 2020-12-16
BIOATLA INC
11085 Torreyana Road
San Diego CALIFORNIA 92121 US
CEO: Jay M. Short
Employees: 61
Phone: 18585580708
BIOATLA INC / BCAB FAQ
What does BIOATLA INC do?
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
What is the current price of BCAB stock?
The current stock price of BCAB is 4.3 USD. The price increased by 0.7% in the last trading session.
Does BCAB stock pay dividends?
BCAB does not pay a dividend.
How is the ChartMill rating for BIOATLA INC?
BCAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is BCAB stock listed?
BCAB stock is listed on the Nasdaq exchange.
What is BIOATLA INC worth?
BIOATLA INC (BCAB) has a market capitalization of 356.25M USD. This makes BCAB a Small Cap stock.